![]() | |
Clinical data | |
---|---|
Trade names | Kerendia |
Other names | BAY 94-8862 |
License data |
|
Pregnancy category | |
Routes of administration | Oral |
Drug class | Potassium-sparing diuretic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.247.614 |
Chemical and physical data | |
Formula | C21H22N4O3 |
Molar mass | 378.432 g·mol−1 |
3D model (JSmol) | |
| |
|
Finerenone, sold under the brand name Kerendia and Firialta, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.[8] Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).[7] It is taken orally (swallowed by mouth).
Common side effects include hyperkalemia (high levels of potassium), hypotension (low blood pressure), and hyponatremia (low levels of sodium).[8]
Finerenone was approved for medical use in the United States in July 2021,[8][10] and in the European Union in February 2022.[9] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[11]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search